Study Title
BlinFant: A pilot study to test the feasibility and safety and efficacy of the addition of the BiTE antibody Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged acute lymphoblastic leukemia (A collaborative study of the Interfant network)
Protocol ID
NL59901.078.17 (BlinFant)
Disease (Sub Disease)
Acute Lymphoblastic Leukaemia (ALL)
Diagnosis Stage
New diagnosis
Sponsor
Australian and New Zealand Children's Haematology Oncology Group
Princess Maxima Center for Pediatric Oncology & Utrecht
Princess Maxima Center for Pediatric Oncology & Utrecht
Links
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Pilot
Age Eligibility
<12 months
ANZCTR
ACTRN12620000542998
| Study Title | BlinFant: A pilot study to test the feasibility and safety and efficacy of the addition of the BiTE antibody Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged acute lymphoblastic leukemia (A collaborative study of the Interfant network) |
|---|---|
| Protocol ID | NL59901.078.17 (BlinFant) |
| Disease (Sub Disease) | Acute Lymphoblastic Leukaemia (ALL) |
| Diagnosis Stage | New diagnosis |
| Sponsor | Australian and New Zealand Children's Haematology Oncology Group/ Princess Maxima Center for Pediatric Oncology & Utrecht |
| Links | https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379482&isReview=true |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 20/07/2018 |
| Study Type | Treatment |
| Phase | Pilot |
| Age Eligibility | <12 months |
| ANZCTR | ACTRN12620000542998 |